Autoinjectors Market by Usage (Reusable, Disposable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Anaphylaxis), Route of administration (SC, IM), Volume (<3ml, >3ml), End User (Home Care, Hospitals) - Global Forecast to 2028
The global autoinjector devices market is projected to reach USD 1.7 billion in 2028 from USD 0.9 billion in 2023, growing at a CAGR of 14.0%. Where as, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. The key factors driving the growth of the autoinjectors market are the increasing availability of generic versions of autoinjectors and advantages offered by autoinjectors in emergency medical care is expected to propel the growth of the market. However, alternative modes of drug delivery such as oral, nasal, and topical among others are expected to restrain market growth to a certain extent.
The autoinjectors market has been segmented based on technology, usage, route of administration, volume, therapy area, end user and region.
“By technology, the manual autoinjectors segment accounted for the largest share of the autoinjectors market”
Based on technology, the autoinjectors market is categorized into manual, and automatic. The manual autoinjectors segment dominated the market in 2022, owing to the advantages that they offer. These include greater patient control, ease of use, improved safety and accuracy among others. Manual autoinjectors allow patinets and caregivers to administer the medication only when they are ready. This allows for more safe and accurate administration of medication dose.
“By end user, the home care settings segment accounted for the largest share in the autoinjectors market”
Based on end user, the autoinjectors market is segmented into home care settings, hospitals and clinics, and ambulatory care settings. In 2022, the home care settings segment accounted for a largest share of the autoinjectors market. Growth in this market segment can be attributed to relatively lower costs incurred for home care therapies than for treatments in hospitals and the ease of self-administration of drugs using autoinjectors.
“North America: the largest share of the autoinjectors market”
North America accounted for the largest share of the autoinjectors market. The large share of the North America region can be attributed to high awareness and adoption of self-administration of medication. Moreover, favorable reimbursements for autoinjectors has contributed to the growth of the market. Developed countries like the US and Canada have been observed to havehigher awareness and thus, adoption of self-administration drug delivery. This is supported by the favorable reimbursements offered by the government, insurance entities among others in the region.
“Asia Pacific: The fastest-growing region in the autoinjectors market.”
The Asia Pacific autoinjectors market is projected to grow at the highest CAGR during the forecast period. This is attributed to the continuously growing pharmaceutical and biopharmaceutical industries offering generic versions of autoinjectors and growing number of approvals for autoinjector products in the region. Besides, the region has presence of large number of geratric population and a high prevalence of chronic disease including diabetes and cardiovascular diseases. Therefore, the adoption of self-administration of medication is expected to increasing owing to the high frequency of these medications.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the autoinjectors market. It aims at estimating the size and future growth potential of the market across different segments, such as the usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapy areas), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autoinjectors market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
The autoinjectors market has been segmented based on technology, usage, route of administration, volume, therapy area, end user and region.
“By technology, the manual autoinjectors segment accounted for the largest share of the autoinjectors market”
Based on technology, the autoinjectors market is categorized into manual, and automatic. The manual autoinjectors segment dominated the market in 2022, owing to the advantages that they offer. These include greater patient control, ease of use, improved safety and accuracy among others. Manual autoinjectors allow patinets and caregivers to administer the medication only when they are ready. This allows for more safe and accurate administration of medication dose.
“By end user, the home care settings segment accounted for the largest share in the autoinjectors market”
Based on end user, the autoinjectors market is segmented into home care settings, hospitals and clinics, and ambulatory care settings. In 2022, the home care settings segment accounted for a largest share of the autoinjectors market. Growth in this market segment can be attributed to relatively lower costs incurred for home care therapies than for treatments in hospitals and the ease of self-administration of drugs using autoinjectors.
“North America: the largest share of the autoinjectors market”
North America accounted for the largest share of the autoinjectors market. The large share of the North America region can be attributed to high awareness and adoption of self-administration of medication. Moreover, favorable reimbursements for autoinjectors has contributed to the growth of the market. Developed countries like the US and Canada have been observed to havehigher awareness and thus, adoption of self-administration drug delivery. This is supported by the favorable reimbursements offered by the government, insurance entities among others in the region.
“Asia Pacific: The fastest-growing region in the autoinjectors market.”
The Asia Pacific autoinjectors market is projected to grow at the highest CAGR during the forecast period. This is attributed to the continuously growing pharmaceutical and biopharmaceutical industries offering generic versions of autoinjectors and growing number of approvals for autoinjector products in the region. Besides, the region has presence of large number of geratric population and a high prevalence of chronic disease including diabetes and cardiovascular diseases. Therefore, the adoption of self-administration of medication is expected to increasing owing to the high frequency of these medications.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
- By Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America- 10%, and Middle East & Africa- 5%
- Becton, Dickinson and Company (BD) (US)
- Ypsomed Holding AG (Switzerland)
- sSHL Medical (Switzerland)
- West Pharmaceutical Services, Inc. (US)
- Recipharm AB (Sweden)
- Haselmeier GmbH (Germany)
- Owen Mumford Ltd. (UK)
- Gerresheimer AG (Germany)
- Phillips-Medisize, LLC (US)
- Oval Medical Technologies Ltd. (UK)
- Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China)
- Elcam Drug Delivery Devices (E3D) (Israel)
- Crossject (France)
- Johnson MedTech, LLC. (US), Antares Pharma, Inc. (US)
- Jabil, Inc. (US)
- Congruence Medical Solutions LLC (US)
- AbbVie Inc. (US)
- Amgen Inc. (US)
- Eli Lilly and Company (US)
- Novartis AG (Switzerland)
- Merck KGaA (Germany)
- Viatris Inc. (US)
- Biogen (US)
This report provides a detailed picture of the autoinjectors market. It aims at estimating the size and future growth potential of the market across different segments, such as the usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapy areas), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autoinjectors market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
- Analysis of key drivers (the benefits of autoinjectors in emergency medical care, growth in the number of regulatory approvals, availability of generic versions of autoinjectors, government support and favorable reimbursements, and the growing adoption of self-administration), restraints (alternative drug delivery modes and needle phobia), opportunities (patent expiry of biologics and the increasing shift of therapy to home settings), and challenges (development of autoinjectors for multiple drug viscosities) influencing the growth of the autoinjectors market.
- Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the autoinjectors market.
- Market Development: Comprehensive information about lucrative markets- the report analyses the autoinjectors market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoinjectors market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Becton, Dickinson and Company (BD), Ypsomed Holding AG, SHL Medical among others in the autoinjectors devices market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 AUTOINJECTORS MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES
FIGURE 4 MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES
FIGURE 5 AUTOINJECTORS MARKET SIZE ESTIMATION: OVERALL APPROACH
FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: APPROACH 1 (REVENUE SHARE ANALYSIS)
2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS
FIGURE 7 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
FIGURE 8 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: APPROACH 1 (REVENUE SHARE ANALYSIS)
2.3.1 INSIGHTS FROM PRIMARIES
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 GROWTH FORECAST
FIGURE 11 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS
FIGURE 12 AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS
FIGURE 13 AUTOINJECTORS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 14 DATA TRIANGULATION METHODOLOGY
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ANALYSIS
2.8 IMPACT OF RECESSION ON AUTOINJECTORS MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 15 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2023 VS. 2028 (USD MILLION)
FIGURE 16 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2023 VS. 2028 (USD BILLION)
FIGURE 17 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
FIGURE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)
FIGURE 19 AUTOINJECTOR DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 20 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 21 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR DEVICES MARKET
FIGURE 22 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR FINISHED FORMULATIONS MARKET
4 PREMIUM INSIGHTS
4.1 AUTOINJECTOR FINISHED FORMULATIONS AND DEVICES MARKET OVERVIEW
FIGURE 23 INCREASING NUMBER OF REGULATORY APPROVALS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SHARE, BY USAGE AND COUNTRY (2022)
FIGURE 24 DISPOSABLE AUTOINJECTORS SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR DEVICES MARKET IN 2022
4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND COUNTRY (2022)
FIGURE 25 SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR FINISHED FORMULATIONS MARKET IN 2022
4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 26 RHEUMATOID ARTHRITIS SEGMENT TO CONTINUE TO DOMINATE MARKET BY 2028
4.5 OVERALL AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2022
FIGURE 27 MANUAL AUTOINJECTORS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 28 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR DEVICES MARKET FROM 2023 TO 2028
4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR FINISHED FORMULATIONS MARKET FROM 2023 TO 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 30 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 AUTOINJECTORS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Benefits of autoinjectors in emergency medical care
5.2.1.2 Increasing regulatory approvals for autoinjectors
TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE
5.2.1.3 Availability of generics and biosimilars in autoinjectors
5.2.1.4 Government support and favorable reimbursements
5.2.1.5 Growing awareness and adoption of self-administration
5.2.2 RESTRAINTS
5.2.2.1 Alternative drug delivery modes and needle phobia
5.2.3 OPPORTUNITIES
5.2.3.1 Patent expiry of biologics
TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS
5.2.3.2 Increasing shift of therapy to home settings
5.2.4 CHALLENGES
5.2.4.1 Development of autoinjectors for multiple drug viscosities
5.3 KEY INDUSTRY TRENDS
5.3.1 INCREASING ADOPTION OF WEARABLE AUTOINJECTORS
5.3.2 DEVELOPMENT AND LAUNCH OF ENVIRONMENT-FRIENDLY AUTOINJECTORS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 31 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOINJECTOR PROVIDERS
5.5 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 2020
TABLE 6 INDICATIVE PRICING ANALYSIS OF AUTOINJECTOR FINISHED FORMULATIONS
5.6 VALUE CHAIN ANALYSIS
FIGURE 32 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 33 AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS
TABLE 7 OVERALL SUPPLY CHAIN ECOSYSTEM FOR AUTOINJECTORS
5.8 ECOSYSTEM ANALYSIS
FIGURE 34 ECOSYSTEM ANALYSIS: AUTOINJECTORS MARKET
5.9 TECHNOLOGY ANALYSIS
5.10 PATENT ANALYSIS
FIGURE 35 PATENT APPLICATIONS FOR AUTOINJECTORS, JANUARY 2012–APRIL 2023
TABLE 8 INDICATIVE LIST OF PATENTS IN AUTOINJECTORS MARKET
5.11 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 9 AUTOINJECTORS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.12 TRADE DATA
TABLE 10 IMPORT AND EXPORT DATA FOR PRODUCTS INCLUDING AUTOINJECTORS, AMONG OTHERS, 2022
5.13 REGULATORY ANALYSIS
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 THREAT OF SUBSTITUTES
5.14.3 BARGAINING POWER OF SUPPLIERS
5.14.4 BARGAINING POWER OF BUYERS
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTOR DEVICES
5.15.2 BUYING CRITERIA FOR AUTOINJECTOR DEVICES
FIGURE 37 KEY BUYING CRITERIA FOR END USERS
6 AUTOINJECTORS MARKET, BY USAGE
6.1 INTRODUCTION
TABLE 16 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 17 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (MILLION UNITS)
TABLE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
6.2 DISPOSABLE AUTOINJECTORS
6.2.1 CONVENIENCE OF USE FOR PATIENTS TO DRIVE GROWTH
TABLE 19 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 21 NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 25 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 REUSABLE AUTOINJECTORS
6.3.1 REUSABLE AUTOINJECTORS TO ACCOUNT FOR LOWER SHARE OF MARKET
TABLE 28 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 29 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 30 NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 34 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 AUTOINJECTORS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 37 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 38 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (MILLION UNITS)
TABLE 39 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 MANUAL AUTOINJECTORS
7.2.1 MANUAL AUTOINJECTORS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE DURING FORECAST PERIOD
TABLE 40 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 42 NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 46 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 AUTOMATIC AUTOINJECTORS
7.3.1 AUTOMATIC AUTOINJECTORS INTEGRATE ELECTRONIC COMPONENTS AND ADDITIONAL FEATURES TO ENHANCE INJECTION PROCESS
TABLE 49 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 50 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 51 NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 55 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
TABLE 58 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 59 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (MILLION UNITS)
8.2 SUBCUTANEOUS
8.2.1 INCREASING NUMBER OF PRODUCT APPROVALS TO DRIVE GROWTH
TABLE 60 AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 SUBCUTANEOUS AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 62 NORTH AMERICA: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 EUROPE: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 ASIA PACIFIC: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 INTRAMUSCULAR
8.3.1 INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES FASTER ABSORPTION OF MEDICATION
TABLE 65 AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 INTRAMUSCULAR AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 67 NORTH AMERICA: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 EUROPE: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 ASIA PACIFIC: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
9 AUTOINJECTORS MARKET, BY THERAPY AREA
9.1 INTRODUCTION
TABLE 70 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 71 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (MILLION UNITS)
TABLE 72 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
9.2 RHEUMATOID ARTHRITIS
9.2.1 BENEFITS OF AUTOINJECTORS IN RHEUMATOID ARTHRITIS TREATMENT TO PROPEL GROWTH
TABLE 73 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 74 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 75 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 DIABETES
9.3.1 LARGE DIABETIC POPULATION TO DRIVE DEMAND FOR AUTOINJECTORS
FIGURE 38 DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20–79 YEARS), 2019 VS. 2030 VS. 2045
TABLE 82 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)
TABLE 83 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 84 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 87 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)
TABLE 88 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 MULTIPLE SCLEROSIS
9.4.1 AVAILABILITY OF ORAL GENERIC MEDICINES TO NEGATIVELY IMPACT GROWTH
TABLE 91 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 92 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 93 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 97 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 99 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
9.4.2 ANAPHYLAXIS
9.4.2.1 Increasing prevalence of food allergies to drive growth
TABLE 100 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 101 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 102 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 106 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
9.4.3 OTHER THERAPY AREAS
TABLE 109 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 110 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 111 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 113 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 115 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
10 AUTOINJECTORS MARKET, BY VOLUME
10.1 INTRODUCTION
TABLE 118 AUTOINJECTORS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 119 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (MILLION UNITS)
10.2 UP TO 3 ML VOLUME
10.2.1 INCREASING USE OF SUBCUTANEOUS INJECTIONS AGAINST CHRONIC DISEASES TO DRIVE GROWTH
TABLE 120 UP TO 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 121 UP TO 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
10.3 ABOVE 3 ML VOLUME (LARGE VOLUME)
10.3.1 GROWING RESEARCH TO STUDY POTENTIAL OF LARGE-VOLUME AUTOINJECTORS TO DRIVE GROWTH
TABLE 122 ABOVE 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 123 ABOVE 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
11 AUTOINJECTORS MARKET, BY END USER
11.1 INTRODUCTION
TABLE 124 AUTOINJECTORS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2 HOME CARE SETTINGS
11.2.1 COST-EFFECTIVENESS OF HOME CARE THERAPIES TO PROPEL GROWTH
TABLE 125 AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 126 NORTH AMERICA: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 127 EUROPE: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 128 ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
11.3 HOSPITALS AND CLINICS
11.3.1 USE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS AND CLINICS TO DRIVE GROWTH
TABLE 129 AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 130 NORTH AMERICA: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 131 EUROPE: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 132 ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
11.4 AMBULATORY CARE SETTINGS
11.4.1 INCREASING PATIENT VOLUME IN AMBULATORY CARE SETTINGS TO DRIVE GROWTH
TABLE 133 AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 134 NORTH AMERICA: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 135 EUROPE: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 136 ASIA PACIFIC: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
12 AUTOINJECTORS MARKET, BY REGION
12.1 INTRODUCTION
TABLE 137 AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 138 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 39 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT
TABLE 139 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 141 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 142 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 143 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 144 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 145 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 146 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 147 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 148 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 149 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 150 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 151 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 152 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.1 US
12.2.1.1 US to dominate North American market during forecast period
TABLE 153 AUTOINJECTORS APPROVED BY US FDA, 2022
TABLE 154 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 155 US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 156 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 157 US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 158 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 159 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 160 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 161 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 162 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 163 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.2 CANADA
12.2.2.1 Rising prevalence of chronic diseases to drive growth
TABLE 164 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 165 CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 166 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 167 CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 168 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 169 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 170 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 171 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 172 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 173 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.3 NORTH AMERICA: RECESSION IMPACT
12.3 EUROPE
TABLE 174 EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 175 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 176 EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 177 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 178 EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 179 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 180 EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 181 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 182 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 183 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 184 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 185 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 186 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 187 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 Growing government support to propel market
TABLE 188 GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 189 GERMANY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 190 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 191 GERMANY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 192 GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 193 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 194 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 195 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 196 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 197 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.2 UK
12.3.2.1 High prevalence of allergic conditions to boost growth
TABLE 198 UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 199 UK: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 200 UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 201 UK: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 202 UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 203 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 204 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 205 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 206 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 207 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.3 FRANCE
12.3.3.1 Increasing prevalence of chronic diseases to support growth
TABLE 208 FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 209 FRANCE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 210 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 211 FRANCE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 212 FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 213 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 214 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 215 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 216 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 217 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.4 ITALY
12.3.4.1 Rising prevalence of chronic diseases to propel growth
TABLE 218 ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 219 ITALY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 220 ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 221 ITALY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 222 ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 223 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 224 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 225 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 226 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 227 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.5 SPAIN
12.3.5.1 Favorable reimbursement scenario to support growth
TABLE 228 SPAIN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 229 SPAIN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 230 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 231 SPAIN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 232 SPAIN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 233 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 234 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 235 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 236 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 237 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.6 REST OF EUROPE
TABLE 238 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 239 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 240 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 241 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 242 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 243 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 244 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 245 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 246 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 247 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.7 EUROPE: RECESSION IMPACT
12.4 ASIA PACIFIC
FIGURE 40 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET SNAPSHOT
TABLE 248 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 249 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 250 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 251 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 252 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 253 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 254 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 255 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 256 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 257 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 258 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 259 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 260 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 261 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.1 JAPAN
12.4.1.1 Presence of large geriatric population to boost growth
TABLE 262 JAPAN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 263 JAPAN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 264 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 265 JAPAN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 266 JAPAN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 267 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 268 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 269 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 270 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 271 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.2 CHINA
12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to drive growth
TABLE 272 CHINA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 273 CHINA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 274 CHINA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 275 CHINA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 276 CHINA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 277 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 278 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 279 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 280 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 281 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.3 INDIA
12.4.3.1 Increasing burden of diabetes and CVD to drive growth
TABLE 282 INDIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 283 INDIA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 284 INDIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 285 INDIA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 286 INDIA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 287 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 288 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 289 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 290 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 291 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.4 SOUTH KOREA
12.4.4.1 Regulatory approvals for autoinjectors to drive growth
TABLE 292 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 293 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 294 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 295 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 296 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 297 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 298 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 299 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 300 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 301 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.5 REST OF ASIA PACIFIC
TABLE 302 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 303 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 304 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 305 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 306 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 307 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 308 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 309 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 310 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 311 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.6 ASIA PACIFIC: RECESSION IMPACT
12.5 LATIN AMERICA
12.5.1 RISING GERIATRIC POPULATION TO SUPPORT GROWTH
TABLE 312 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 313 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 314 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 315 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 316 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 317 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 318 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 319 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 320 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 321 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 322 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 323 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5.2 LATIN AMERICA: RECESSION IMPACT
12.6 MIDDLE EAST & AFRICA
12.6.1 FAVORABLE REFORMS IN AFRICA AND MIDDLE EASTERN COUNTRIES TO DRIVE GROWTH
TABLE 324 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 325 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 326 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 327 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 328 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 329 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 330 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 331 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 332 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 333 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 334 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 335 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 41 AUTOINJECTOR DEVICES AND FINISHED FORMULATIONS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
13.3 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR DEVICES MARKET
FIGURE 42 AUTOINJECTOR DEVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
13.4 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET
FIGURE 43 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
13.5 MARKET SHARE ANALYSIS FOR AUTOINJECTOR DEVICES MARKET
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET, 2022
TABLE 336 AUTOINJECTOR DEVICES MARKET: DEGREE OF COMPETITION
13.6 MARKET SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET
FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET, 2022
TABLE 337 AUTOINJECTOR FINISHED FORMULATIONS MARKET: DEGREE OF COMPETITION
13.7 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
FIGURE 46 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
13.8.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 338 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
13.8.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 339 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES
FIGURE 47 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
13.9.1 PROGRESSIVE COMPANIES
13.9.2 STARTING BLOCKS
13.9.3 RESPONSIVE COMPANIES
13.9.4 DYNAMIC COMPANIES
13.10 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 340 AUTOINJECTORS MARKET: LIST OF KEY STARTUP/SME PLAYERS
TABLE 341 AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
13.11 COMPETITIVE SCENARIO AND TRENDS
13.11.1 PRODUCT LAUNCHES
TABLE 342 AUTOINJECTORS MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023
13.11.2 DEALS
TABLE 343 AUTOINJECTORS MARKET: DEALS, JANUARY 2020–APRIL 2023
13.11.3 OTHER DEVELOPMENTS
TABLE 344 AUTOINJECTORS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023
13.11.4 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
TABLE 345 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
13.11.5 DEVICES FOR LARGE-VOLUME FORMULATIONS
TABLE 346 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS
13.11.6 DEVICES FOR HIGHLY VISCOUS FORMULATIONS
TABLE 347 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS
TABLE 348 FORMULATIONS AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS
13.11.7 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET
14 COMPANY PROFILES
14.1 KEY PLAYERS: DEVICES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 BECTON, DICKINSON AND COMPANY (BD)
TABLE 349 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 350 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS
TABLE 351 BECTON, DICKINSON AND COMPANY: DEALS
TABLE 352 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS
14.1.2 YPSOMED HOLDING AG
TABLE 353 YPSOMED HOLDING AG: COMPANY OVERVIEW
FIGURE 49 YPSOMED HOLDING AG: COMPANY SNAPSHOT
TABLE 354 YPSOMED HOLDING AG: PRODUCT OFFERINGS
TABLE 355 YPSOMED HOLDING AG: PRODUCT LAUNCHES
TABLE 356 YPSOMED HOLDING AG: DEALS
14.1.3 SHL MEDICAL
TABLE 357 SHL MEDICAL: COMPANY OVERVIEW
TABLE 358 SHL MEDICAL: PRODUCT OFFERINGS
TABLE 359 SHL MEDICAL: DEALS
TABLE 360 SHL MEDICAL: OTHER DEVELOPMENTS
14.1.4 WEST PHARMACEUTICAL SERVICES, INC.
TABLE 361 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
FIGURE 50 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2022)
TABLE 362 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT OFFERINGS
TABLE 363 WEST PHARMACEUTICAL SERVICES, INC.: OTHER DEVELOPMENTS
14.1.5 RECIPHARM AB
TABLE 364 RECIPHARM AB: COMPANY OVERVIEW
TABLE 365 RECIPHARM AB: PRODUCT OFFERINGS
TABLE 366 RECIPHARM AB: DEALS
14.1.6 HASELMEIER GMBH
TABLE 367 HASELMEIER GMBH: COMPANY OVERVIEW
TABLE 368 HASELMEIER GMBH: PRODUCT OFFERINGS
TABLE 369 HASELMEIER GMBH: DEALS
TABLE 370 HASELMEIER GMBH: PRODUCT LAUNCHES
14.1.7 OWEN MUMFORD LTD.
TABLE 371 OWEN MUMFORD LTD.: COMPANY OVERVIEW
TABLE 372 OWEN MUMFORD LTD.: PRODUCT OFFERINGS
TABLE 373 OWEN MUMFORD LTD.: PRODUCT LAUNCHES
TABLE 374 OWEN MUMFORD LTD.: DEALS
TABLE 375 OWEN MUMFORD LTD.: OTHER DEVELOPMENTS
14.1.8 GERRESHEIMER AG
TABLE 376 GERRESHEIMER AG: COMPANY OVERVIEW
FIGURE 51 GERRESHEIMER AG: COMPANY SNAPSHOT (2022)
TABLE 377 GERRESHEIMER AG: PRODUCT OFFERINGS
TABLE 378 GERRESHEIMER AG: DEALS
14.1.9 PHILLIPS-MEDISIZE, LLC
TABLE 379 PHILIPS-MEDISIZE, LLC: COMPANY OVERVIEW
TABLE 380 PHILIPS MEDISIZE, LLC: PRODUCT OFFERINGS
TABLE 381 PHILIPS MEDISIZE, LLC: PRODUCT LAUNCHES
TABLE 382 PHILIPS-MEDISIZE, LLC: OTHER DEVELOPMENTS
14.1.10 OVAL MEDICAL TECHNOLOGIES LTD. (PART OF SMC LTD.)
TABLE 383 OVAL MEDICAL TECHNOLOGIES LTD.: COMPANY OVERVIEW
TABLE 384 OVAL MEDICAL TECHNOLOGIES LTD.: PRODUCT OFFERINGS
14.1.11 KALEO, INC.
TABLE 385 KALEO, INC.: COMPANY OVERVIEW
TABLE 386 KALEO, INC.: PRODUCT OFFERINGS
14.1.12 SOLTEAM INCORPORATION CO., LTD.
TABLE 387 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW
TABLE 388 SOLTEAM INCORPORATION CO., LTD.: PRODUCT OFFERINGS
14.1.13 ELCAM DRUG DELIVERY DEVICES (E3D)
14.1.14 CROSSJECT
TABLE 391 CROSSJECT: COMPANY OVERVIEW
TABLE 392 CROSSJECT: PRODUCT OFFERINGS
14.1.15 JOHNSON MEDTECH, LLC. (PART OF JOHNSON ELECTRIC HOLDINGS LTD.)
TABLE 393 JOHNSON MEDTECH, LLC.: COMPANY OVERVIEW
TABLE 394 JOHNSON MEDTECH, LLC: PRODUCT OFFERINGS
14.1.16 ANTARES PHARMA, INC. (PART OF HALOZYME, INC.)
TABLE 395 ANTARES PHARMA, INC.: COMPANY OVERVIEW
FIGURE 52 ANTARES PHARMA, INC.: COMPANY SNAPSHOT
TABLE 396 ANTARES PHARMA, INC.: PRODUCT OFFERINGS
TABLE 397 ANTARES PHARMA, INC.: DEALS
14.1.17 JABIL, INC.
TABLE 398 JABIL, INC.: COMPANY OVERVIEW
TABLE 399 JABIL INC.: PRODUCT OFFERINGS
14.1.18 CONGRUENCE MEDICAL SOLUTIONS LLC
TABLE 400 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW
TABLE 401 CONGRUENCE MEDICAL SOLUTIONS LLC: PRODUCT OFFERINGS
14.2 KEY PLAYERS: FINISHED FORMULATIONS
14.2.1 ABBVIE INC.
TABLE 402 ABBVIE INC.: COMPANY OVERVIEW
FIGURE 53 ABBVIE INC.: COMPANY SNAPSHOT
TABLE 403 ABBVIE INC.: PRODUCT OFFERINGS
TABLE 404 ABBVIE INC.: PRODUCT LAUNCHES
TABLE 405 ABBVIE INC.: OTHER DEVELOPMENTS
14.2.2 AMGEN INC.
TABLE 406 AMGEN INC.: COMPANY OVERVIEW
FIGURE 54 AMGEN INC.: COMPANY SNAPSHOT
TABLE 407 AMGEN INC.: PRODUCT OFFERINGS
TABLE 408 AMGEN INC.: PRODUCT LAUNCHES
14.2.3 ELI LILLY AND COMPANY
TABLE 409 ELI LILY AND COMPANY: COMPANY OVERVIEW
FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 410 ELI LILY AND COMPANY: PRODUCT OFFERINGS
TABLE 411 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
14.2.4 NOVARTIS AG
TABLE 412 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT
TABLE 413 NOVARTIS AG: PRODUCT OFFERINGS
TABLE 414 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS
14.2.5 MERCK KGAA
TABLE 415 MERCK KGAA: COMPANY OVERVIEW
FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT
TABLE 416 MERCK KGAA: PRODUCT OFFERINGS
14.2.6 VIATRIS INC. (FORMERLY MYLAN INC.)
TABLE 417 VIATRIS INC.: COMPANY OVERVIEW
FIGURE 58 VIATRIS INC.: COMPANY SNAPSHOT
TABLE 418 VIATRIS INC.: PRODUCT OFFERINGS
14.2.7 BIOGEN
TABLE 419 BIOGEN: COMPANY OVERVIEW
FIGURE 59 BIOGEN: COMPANY SNAPSHOT
TABLE 420 BIOGEN: PRODUCT OFFERINGS
TABLE 421 BIOGEN: OTHER DEVELOPMENTS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 AUTOINJECTORS MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES
FIGURE 4 MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES
FIGURE 5 AUTOINJECTORS MARKET SIZE ESTIMATION: OVERALL APPROACH
FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: APPROACH 1 (REVENUE SHARE ANALYSIS)
2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS
FIGURE 7 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
FIGURE 8 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: APPROACH 1 (REVENUE SHARE ANALYSIS)
2.3.1 INSIGHTS FROM PRIMARIES
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 GROWTH FORECAST
FIGURE 11 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS
FIGURE 12 AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS
FIGURE 13 AUTOINJECTORS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 14 DATA TRIANGULATION METHODOLOGY
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ANALYSIS
2.8 IMPACT OF RECESSION ON AUTOINJECTORS MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
3 EXECUTIVE SUMMARY
FIGURE 15 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2023 VS. 2028 (USD MILLION)
FIGURE 16 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2023 VS. 2028 (USD BILLION)
FIGURE 17 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
FIGURE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)
FIGURE 19 AUTOINJECTOR DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 20 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 21 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR DEVICES MARKET
FIGURE 22 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR FINISHED FORMULATIONS MARKET
4 PREMIUM INSIGHTS
4.1 AUTOINJECTOR FINISHED FORMULATIONS AND DEVICES MARKET OVERVIEW
FIGURE 23 INCREASING NUMBER OF REGULATORY APPROVALS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SHARE, BY USAGE AND COUNTRY (2022)
FIGURE 24 DISPOSABLE AUTOINJECTORS SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR DEVICES MARKET IN 2022
4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND COUNTRY (2022)
FIGURE 25 SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR FINISHED FORMULATIONS MARKET IN 2022
4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 26 RHEUMATOID ARTHRITIS SEGMENT TO CONTINUE TO DOMINATE MARKET BY 2028
4.5 OVERALL AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2022
FIGURE 27 MANUAL AUTOINJECTORS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 28 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR DEVICES MARKET FROM 2023 TO 2028
4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR FINISHED FORMULATIONS MARKET FROM 2023 TO 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 30 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 AUTOINJECTORS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Benefits of autoinjectors in emergency medical care
5.2.1.2 Increasing regulatory approvals for autoinjectors
TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE
5.2.1.3 Availability of generics and biosimilars in autoinjectors
5.2.1.4 Government support and favorable reimbursements
5.2.1.5 Growing awareness and adoption of self-administration
5.2.2 RESTRAINTS
5.2.2.1 Alternative drug delivery modes and needle phobia
5.2.3 OPPORTUNITIES
5.2.3.1 Patent expiry of biologics
TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS
5.2.3.2 Increasing shift of therapy to home settings
5.2.4 CHALLENGES
5.2.4.1 Development of autoinjectors for multiple drug viscosities
5.3 KEY INDUSTRY TRENDS
5.3.1 INCREASING ADOPTION OF WEARABLE AUTOINJECTORS
5.3.2 DEVELOPMENT AND LAUNCH OF ENVIRONMENT-FRIENDLY AUTOINJECTORS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 31 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOINJECTOR PROVIDERS
5.5 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 2020
TABLE 6 INDICATIVE PRICING ANALYSIS OF AUTOINJECTOR FINISHED FORMULATIONS
5.6 VALUE CHAIN ANALYSIS
FIGURE 32 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 33 AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS
TABLE 7 OVERALL SUPPLY CHAIN ECOSYSTEM FOR AUTOINJECTORS
5.8 ECOSYSTEM ANALYSIS
FIGURE 34 ECOSYSTEM ANALYSIS: AUTOINJECTORS MARKET
5.9 TECHNOLOGY ANALYSIS
5.10 PATENT ANALYSIS
FIGURE 35 PATENT APPLICATIONS FOR AUTOINJECTORS, JANUARY 2012–APRIL 2023
TABLE 8 INDICATIVE LIST OF PATENTS IN AUTOINJECTORS MARKET
5.11 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 9 AUTOINJECTORS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.12 TRADE DATA
TABLE 10 IMPORT AND EXPORT DATA FOR PRODUCTS INCLUDING AUTOINJECTORS, AMONG OTHERS, 2022
5.13 REGULATORY ANALYSIS
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 THREAT OF SUBSTITUTES
5.14.3 BARGAINING POWER OF SUPPLIERS
5.14.4 BARGAINING POWER OF BUYERS
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTOR DEVICES
5.15.2 BUYING CRITERIA FOR AUTOINJECTOR DEVICES
FIGURE 37 KEY BUYING CRITERIA FOR END USERS
6 AUTOINJECTORS MARKET, BY USAGE
6.1 INTRODUCTION
TABLE 16 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 17 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (MILLION UNITS)
TABLE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
6.2 DISPOSABLE AUTOINJECTORS
6.2.1 CONVENIENCE OF USE FOR PATIENTS TO DRIVE GROWTH
TABLE 19 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 21 NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 25 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 REUSABLE AUTOINJECTORS
6.3.1 REUSABLE AUTOINJECTORS TO ACCOUNT FOR LOWER SHARE OF MARKET
TABLE 28 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 29 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 30 NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 34 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 AUTOINJECTORS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 37 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 38 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (MILLION UNITS)
TABLE 39 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 MANUAL AUTOINJECTORS
7.2.1 MANUAL AUTOINJECTORS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE DURING FORECAST PERIOD
TABLE 40 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 42 NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 46 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 AUTOMATIC AUTOINJECTORS
7.3.1 AUTOMATIC AUTOINJECTORS INTEGRATE ELECTRONIC COMPONENTS AND ADDITIONAL FEATURES TO ENHANCE INJECTION PROCESS
TABLE 49 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 50 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 51 NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 55 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
TABLE 58 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 59 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (MILLION UNITS)
8.2 SUBCUTANEOUS
8.2.1 INCREASING NUMBER OF PRODUCT APPROVALS TO DRIVE GROWTH
TABLE 60 AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 SUBCUTANEOUS AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 62 NORTH AMERICA: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 EUROPE: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 ASIA PACIFIC: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 INTRAMUSCULAR
8.3.1 INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES FASTER ABSORPTION OF MEDICATION
TABLE 65 AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 INTRAMUSCULAR AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 67 NORTH AMERICA: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 EUROPE: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 ASIA PACIFIC: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
9 AUTOINJECTORS MARKET, BY THERAPY AREA
9.1 INTRODUCTION
TABLE 70 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 71 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (MILLION UNITS)
TABLE 72 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
9.2 RHEUMATOID ARTHRITIS
9.2.1 BENEFITS OF AUTOINJECTORS IN RHEUMATOID ARTHRITIS TREATMENT TO PROPEL GROWTH
TABLE 73 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 74 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 75 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 80 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 DIABETES
9.3.1 LARGE DIABETIC POPULATION TO DRIVE DEMAND FOR AUTOINJECTORS
FIGURE 38 DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20–79 YEARS), 2019 VS. 2030 VS. 2045
TABLE 82 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)
TABLE 83 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 84 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 86 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 87 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)
TABLE 88 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 MULTIPLE SCLEROSIS
9.4.1 AVAILABILITY OF ORAL GENERIC MEDICINES TO NEGATIVELY IMPACT GROWTH
TABLE 91 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 92 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 93 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 97 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 99 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021–2028 (USD MILLION)
9.4.2 ANAPHYLAXIS
9.4.2.1 Increasing prevalence of food allergies to drive growth
TABLE 100 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 101 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 102 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 106 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021–2028 (USD MILLION)
9.4.3 OTHER THERAPY AREAS
TABLE 109 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 110 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (MILLION UNITS)
TABLE 111 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 113 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021–2028 (USD MILLION)
TABLE 115 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
10 AUTOINJECTORS MARKET, BY VOLUME
10.1 INTRODUCTION
TABLE 118 AUTOINJECTORS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 119 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (MILLION UNITS)
10.2 UP TO 3 ML VOLUME
10.2.1 INCREASING USE OF SUBCUTANEOUS INJECTIONS AGAINST CHRONIC DISEASES TO DRIVE GROWTH
TABLE 120 UP TO 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 121 UP TO 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
10.3 ABOVE 3 ML VOLUME (LARGE VOLUME)
10.3.1 GROWING RESEARCH TO STUDY POTENTIAL OF LARGE-VOLUME AUTOINJECTORS TO DRIVE GROWTH
TABLE 122 ABOVE 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 123 ABOVE 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (MILLION UNITS)
11 AUTOINJECTORS MARKET, BY END USER
11.1 INTRODUCTION
TABLE 124 AUTOINJECTORS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2 HOME CARE SETTINGS
11.2.1 COST-EFFECTIVENESS OF HOME CARE THERAPIES TO PROPEL GROWTH
TABLE 125 AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 126 NORTH AMERICA: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 127 EUROPE: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 128 ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
11.3 HOSPITALS AND CLINICS
11.3.1 USE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS AND CLINICS TO DRIVE GROWTH
TABLE 129 AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 130 NORTH AMERICA: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 131 EUROPE: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 132 ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
11.4 AMBULATORY CARE SETTINGS
11.4.1 INCREASING PATIENT VOLUME IN AMBULATORY CARE SETTINGS TO DRIVE GROWTH
TABLE 133 AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)
TABLE 134 NORTH AMERICA: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 135 EUROPE: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 136 ASIA PACIFIC: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021–2028 (USD MILLION)
12 AUTOINJECTORS MARKET, BY REGION
12.1 INTRODUCTION
TABLE 137 AUTOINJECTOR DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 138 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021–2028 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 39 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT
TABLE 139 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 141 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 142 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 143 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 144 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 145 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 146 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 147 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 148 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 149 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 150 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 151 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 152 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.1 US
12.2.1.1 US to dominate North American market during forecast period
TABLE 153 AUTOINJECTORS APPROVED BY US FDA, 2022
TABLE 154 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 155 US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 156 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 157 US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 158 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 159 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 160 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 161 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 162 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 163 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.2 CANADA
12.2.2.1 Rising prevalence of chronic diseases to drive growth
TABLE 164 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 165 CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 166 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 167 CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 168 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 169 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 170 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 171 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 172 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 173 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.2.3 NORTH AMERICA: RECESSION IMPACT
12.3 EUROPE
TABLE 174 EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 175 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 176 EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 177 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 178 EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 179 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 180 EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 181 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 182 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 183 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 184 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 185 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 186 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 187 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 Growing government support to propel market
TABLE 188 GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 189 GERMANY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 190 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 191 GERMANY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 192 GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 193 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 194 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 195 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 196 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 197 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.2 UK
12.3.2.1 High prevalence of allergic conditions to boost growth
TABLE 198 UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 199 UK: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 200 UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 201 UK: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 202 UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 203 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 204 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 205 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 206 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 207 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.3 FRANCE
12.3.3.1 Increasing prevalence of chronic diseases to support growth
TABLE 208 FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 209 FRANCE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 210 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 211 FRANCE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 212 FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 213 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 214 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 215 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 216 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 217 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.4 ITALY
12.3.4.1 Rising prevalence of chronic diseases to propel growth
TABLE 218 ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 219 ITALY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 220 ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 221 ITALY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 222 ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 223 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 224 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 225 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 226 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 227 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.5 SPAIN
12.3.5.1 Favorable reimbursement scenario to support growth
TABLE 228 SPAIN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 229 SPAIN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 230 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 231 SPAIN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 232 SPAIN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 233 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 234 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 235 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 236 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 237 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.6 REST OF EUROPE
TABLE 238 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 239 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 240 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 241 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 242 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 243 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 244 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 245 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 246 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 247 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.3.7 EUROPE: RECESSION IMPACT
12.4 ASIA PACIFIC
FIGURE 40 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET SNAPSHOT
TABLE 248 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 249 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 250 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 251 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 252 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 253 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 254 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 255 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 256 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 257 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 258 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 259 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 260 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 261 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.1 JAPAN
12.4.1.1 Presence of large geriatric population to boost growth
TABLE 262 JAPAN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 263 JAPAN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 264 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 265 JAPAN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 266 JAPAN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 267 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 268 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 269 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 270 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 271 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.2 CHINA
12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to drive growth
TABLE 272 CHINA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 273 CHINA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 274 CHINA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 275 CHINA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 276 CHINA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 277 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 278 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 279 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 280 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 281 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.3 INDIA
12.4.3.1 Increasing burden of diabetes and CVD to drive growth
TABLE 282 INDIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 283 INDIA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 284 INDIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 285 INDIA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 286 INDIA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 287 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 288 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 289 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 290 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 291 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.4 SOUTH KOREA
12.4.4.1 Regulatory approvals for autoinjectors to drive growth
TABLE 292 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 293 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 294 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 295 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 296 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 297 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 298 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 299 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 300 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 301 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.5 REST OF ASIA PACIFIC
TABLE 302 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 303 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 304 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 305 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 306 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 307 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 308 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 309 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 310 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 311 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.4.6 ASIA PACIFIC: RECESSION IMPACT
12.5 LATIN AMERICA
12.5.1 RISING GERIATRIC POPULATION TO SUPPORT GROWTH
TABLE 312 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 313 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 314 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 315 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 316 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 317 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 318 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 319 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 320 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 321 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 322 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 323 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.5.2 LATIN AMERICA: RECESSION IMPACT
12.6 MIDDLE EAST & AFRICA
12.6.1 FAVORABLE REFORMS IN AFRICA AND MIDDLE EASTERN COUNTRIES TO DRIVE GROWTH
TABLE 324 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 325 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 326 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 327 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 328 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 329 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
TABLE 330 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021–2028 (USD MILLION)
TABLE 331 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 332 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION)
TABLE 333 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021–2028 (USD MILLION)
TABLE 334 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021–2028 (USD MILLION)
TABLE 335 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021–2028 (USD MILLION)
12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 41 AUTOINJECTOR DEVICES AND FINISHED FORMULATIONS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
13.3 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR DEVICES MARKET
FIGURE 42 AUTOINJECTOR DEVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
13.4 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET
FIGURE 43 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
13.5 MARKET SHARE ANALYSIS FOR AUTOINJECTOR DEVICES MARKET
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET, 2022
TABLE 336 AUTOINJECTOR DEVICES MARKET: DEGREE OF COMPETITION
13.6 MARKET SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET
FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET, 2022
TABLE 337 AUTOINJECTOR FINISHED FORMULATIONS MARKET: DEGREE OF COMPETITION
13.7 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
FIGURE 46 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
13.8.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 338 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
13.8.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 339 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES
FIGURE 47 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
13.9.1 PROGRESSIVE COMPANIES
13.9.2 STARTING BLOCKS
13.9.3 RESPONSIVE COMPANIES
13.9.4 DYNAMIC COMPANIES
13.10 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 340 AUTOINJECTORS MARKET: LIST OF KEY STARTUP/SME PLAYERS
TABLE 341 AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
13.11 COMPETITIVE SCENARIO AND TRENDS
13.11.1 PRODUCT LAUNCHES
TABLE 342 AUTOINJECTORS MARKET: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023
13.11.2 DEALS
TABLE 343 AUTOINJECTORS MARKET: DEALS, JANUARY 2020–APRIL 2023
13.11.3 OTHER DEVELOPMENTS
TABLE 344 AUTOINJECTORS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023
13.11.4 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
TABLE 345 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
13.11.5 DEVICES FOR LARGE-VOLUME FORMULATIONS
TABLE 346 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS
13.11.6 DEVICES FOR HIGHLY VISCOUS FORMULATIONS
TABLE 347 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS
TABLE 348 FORMULATIONS AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS
13.11.7 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET
14 COMPANY PROFILES
14.1 KEY PLAYERS: DEVICES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 BECTON, DICKINSON AND COMPANY (BD)
TABLE 349 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 350 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS
TABLE 351 BECTON, DICKINSON AND COMPANY: DEALS
TABLE 352 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS
14.1.2 YPSOMED HOLDING AG
TABLE 353 YPSOMED HOLDING AG: COMPANY OVERVIEW
FIGURE 49 YPSOMED HOLDING AG: COMPANY SNAPSHOT
TABLE 354 YPSOMED HOLDING AG: PRODUCT OFFERINGS
TABLE 355 YPSOMED HOLDING AG: PRODUCT LAUNCHES
TABLE 356 YPSOMED HOLDING AG: DEALS
14.1.3 SHL MEDICAL
TABLE 357 SHL MEDICAL: COMPANY OVERVIEW
TABLE 358 SHL MEDICAL: PRODUCT OFFERINGS
TABLE 359 SHL MEDICAL: DEALS
TABLE 360 SHL MEDICAL: OTHER DEVELOPMENTS
14.1.4 WEST PHARMACEUTICAL SERVICES, INC.
TABLE 361 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
FIGURE 50 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2022)
TABLE 362 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT OFFERINGS
TABLE 363 WEST PHARMACEUTICAL SERVICES, INC.: OTHER DEVELOPMENTS
14.1.5 RECIPHARM AB
TABLE 364 RECIPHARM AB: COMPANY OVERVIEW
TABLE 365 RECIPHARM AB: PRODUCT OFFERINGS
TABLE 366 RECIPHARM AB: DEALS
14.1.6 HASELMEIER GMBH
TABLE 367 HASELMEIER GMBH: COMPANY OVERVIEW
TABLE 368 HASELMEIER GMBH: PRODUCT OFFERINGS
TABLE 369 HASELMEIER GMBH: DEALS
TABLE 370 HASELMEIER GMBH: PRODUCT LAUNCHES
14.1.7 OWEN MUMFORD LTD.
TABLE 371 OWEN MUMFORD LTD.: COMPANY OVERVIEW
TABLE 372 OWEN MUMFORD LTD.: PRODUCT OFFERINGS
TABLE 373 OWEN MUMFORD LTD.: PRODUCT LAUNCHES
TABLE 374 OWEN MUMFORD LTD.: DEALS
TABLE 375 OWEN MUMFORD LTD.: OTHER DEVELOPMENTS
14.1.8 GERRESHEIMER AG
TABLE 376 GERRESHEIMER AG: COMPANY OVERVIEW
FIGURE 51 GERRESHEIMER AG: COMPANY SNAPSHOT (2022)
TABLE 377 GERRESHEIMER AG: PRODUCT OFFERINGS
TABLE 378 GERRESHEIMER AG: DEALS
14.1.9 PHILLIPS-MEDISIZE, LLC
TABLE 379 PHILIPS-MEDISIZE, LLC: COMPANY OVERVIEW
TABLE 380 PHILIPS MEDISIZE, LLC: PRODUCT OFFERINGS
TABLE 381 PHILIPS MEDISIZE, LLC: PRODUCT LAUNCHES
TABLE 382 PHILIPS-MEDISIZE, LLC: OTHER DEVELOPMENTS
14.1.10 OVAL MEDICAL TECHNOLOGIES LTD. (PART OF SMC LTD.)
TABLE 383 OVAL MEDICAL TECHNOLOGIES LTD.: COMPANY OVERVIEW
TABLE 384 OVAL MEDICAL TECHNOLOGIES LTD.: PRODUCT OFFERINGS
14.1.11 KALEO, INC.
TABLE 385 KALEO, INC.: COMPANY OVERVIEW
TABLE 386 KALEO, INC.: PRODUCT OFFERINGS
14.1.12 SOLTEAM INCORPORATION CO., LTD.
TABLE 387 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW
TABLE 388 SOLTEAM INCORPORATION CO., LTD.: PRODUCT OFFERINGS
14.1.13 ELCAM DRUG DELIVERY DEVICES (E3D)
14.1.14 CROSSJECT
TABLE 391 CROSSJECT: COMPANY OVERVIEW
TABLE 392 CROSSJECT: PRODUCT OFFERINGS
14.1.15 JOHNSON MEDTECH, LLC. (PART OF JOHNSON ELECTRIC HOLDINGS LTD.)
TABLE 393 JOHNSON MEDTECH, LLC.: COMPANY OVERVIEW
TABLE 394 JOHNSON MEDTECH, LLC: PRODUCT OFFERINGS
14.1.16 ANTARES PHARMA, INC. (PART OF HALOZYME, INC.)
TABLE 395 ANTARES PHARMA, INC.: COMPANY OVERVIEW
FIGURE 52 ANTARES PHARMA, INC.: COMPANY SNAPSHOT
TABLE 396 ANTARES PHARMA, INC.: PRODUCT OFFERINGS
TABLE 397 ANTARES PHARMA, INC.: DEALS
14.1.17 JABIL, INC.
TABLE 398 JABIL, INC.: COMPANY OVERVIEW
TABLE 399 JABIL INC.: PRODUCT OFFERINGS
14.1.18 CONGRUENCE MEDICAL SOLUTIONS LLC
TABLE 400 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW
TABLE 401 CONGRUENCE MEDICAL SOLUTIONS LLC: PRODUCT OFFERINGS
14.2 KEY PLAYERS: FINISHED FORMULATIONS
14.2.1 ABBVIE INC.
TABLE 402 ABBVIE INC.: COMPANY OVERVIEW
FIGURE 53 ABBVIE INC.: COMPANY SNAPSHOT
TABLE 403 ABBVIE INC.: PRODUCT OFFERINGS
TABLE 404 ABBVIE INC.: PRODUCT LAUNCHES
TABLE 405 ABBVIE INC.: OTHER DEVELOPMENTS
14.2.2 AMGEN INC.
TABLE 406 AMGEN INC.: COMPANY OVERVIEW
FIGURE 54 AMGEN INC.: COMPANY SNAPSHOT
TABLE 407 AMGEN INC.: PRODUCT OFFERINGS
TABLE 408 AMGEN INC.: PRODUCT LAUNCHES
14.2.3 ELI LILLY AND COMPANY
TABLE 409 ELI LILY AND COMPANY: COMPANY OVERVIEW
FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 410 ELI LILY AND COMPANY: PRODUCT OFFERINGS
TABLE 411 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
14.2.4 NOVARTIS AG
TABLE 412 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT
TABLE 413 NOVARTIS AG: PRODUCT OFFERINGS
TABLE 414 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS
14.2.5 MERCK KGAA
TABLE 415 MERCK KGAA: COMPANY OVERVIEW
FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT
TABLE 416 MERCK KGAA: PRODUCT OFFERINGS
14.2.6 VIATRIS INC. (FORMERLY MYLAN INC.)
TABLE 417 VIATRIS INC.: COMPANY OVERVIEW
FIGURE 58 VIATRIS INC.: COMPANY SNAPSHOT
TABLE 418 VIATRIS INC.: PRODUCT OFFERINGS
14.2.7 BIOGEN
TABLE 419 BIOGEN: COMPANY OVERVIEW
FIGURE 59 BIOGEN: COMPANY SNAPSHOT
TABLE 420 BIOGEN: PRODUCT OFFERINGS
TABLE 421 BIOGEN: OTHER DEVELOPMENTS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
